Aktienanalyse zu Neogen Corp (NEOG)NEOGNeogen Corp

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, which reflects strong confidence in future performance. Additionally, the stock has shown a remarkable year-to-date change of +68.71% and a one-year change of +100.51%, indicating robust growth. However, a key risk is the current RSI of 40.44, suggesting that the stock may be approaching oversold territory, which could lead to short-term volatility.

7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.